GE Healthcare, an integral part of
General Electric Company
), recently announced that it has received the European Union's
approval for marketing its VIZAMYL (Flutemetamol (18F) Solution for
Injection). VIZAMYL is a radiopharmaceutical medicinal product for
Positron Emission Tomography (PET) imaging of beta amyloid plaque
in brains of adult patients suffering from cognitive diseases.
VIZAMYL will enable patients to get a neurological diagnosis of
diseases such as Alzheimer's (AD).
General Electric's VIZAMYL is the only diagnostic PET imaging
tracer approved in the Euproean Union for detection of beta amyloid
and visual interpretation of colour images. Along with the
commercial launch of VIZAMYL in early 2015, GE Healthcare has also
developed a mandatory electronic reader training program (ETP) for
readers of VIZAMYL images.
GE Healthcare provides transformational medical technologies and
services by ensuring greater access to enhanced quality and
affordable healthcare facilities across the globe. The approval is
likely to further expand the scope of innovative diagnostic
technologies for more accurate assessment of specific patients
evaluated for Alzheimer's disease and support further research into
the required disease modifying agents.
General Electric, the parent company of GE Healthcare, is one of
the most diversified technologies and financial service
corporations in the world. Its segments include Power & Water,
Oil & Gas, Energy Management, Aviation, Healthcare,
Transportation, Home & Business Solutions, and GE Capital.
General Electric currently has a Zacks Rank #3 (Hold). Other
stocks that look promising in the industry include Federal Signal
), Macquarie Infrastructure Company LLC. (
) and ITT Corporation (
), each having a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research?
Today, you can download 7 Best Stocks for the Next 30 Days.
Click to get this free report
ITT CORP (ITT): Free Stock Analysis Report
GENL ELECTRIC (GE): Free Stock Analysis Report
FED SIGNAL CP (FSS): Free Stock Analysis Report
MACQUARIE INFRA (MIC): Free Stock Analysis
To read this article on Zacks.com click here.